Client Alerts & Insights
Insulet Corp. May Have to Choose Between $452 Million Jury Award or Permanently Blocking Competitor From Utilizing Its Trade Secrets
March 17, 2025
Authored By:
After receiving a jury verdict awarding $452 million in damages against a rival company for misappropriation of trade secrets, the prevailing party, Insulet Corp., may have to choose between portions of the damages award or permanently blocking the rival company from continuing to sell its products based on the stolen technology.
In August 2023, Insulet, a medical device company, sued a rival company, EOFlow, for misappropriation of Insulet’s trade secrets. On December 3, 2024, after a four-week trial in the District of Massachusetts, the jury returned a verdict in favor of Insulet finding that EOFlow misappropriated four of Insulet’s trade secrets in creating its insulin patch pump. The jury awarded Insulet $170 million in compensatory damages and $282 million in exemplary or punitive damages, totaling $452 million.
Shortly after Insulet’s victory, Insulet filed a motion to permanently stop EOFlow from selling the insulin patch pump that it created based on Insulet’s proprietary technology. EOFlow challenged Insulet’s request arguing that, if granted, the injunction would overlap with the damages awarded by the jury which, in part, compensate Insulet for EOFlow’s future profits from its insulin patch product.
Recognizing that a company should not be able to continue to use and profit from stolen trade secrets, Chief U.S. District Judge F. Dennis Saylor IV concluded that some type of injunction would be required. Judge Saylor also concluded that Insulet could not receive both an injunction and keep the full jury award since the relief would overlap. Instead, Judge Saylor suggested Insulet choose whether it wants injunctive relief or the portion of the jury award that captures “unrealized value” from the trade secrets. With Judge Saylor’s proposal as one option, he directed the parties to file new briefs with proposals on how to reconcile the competing interests.
The outcome of Insulet and EOFlow’s post-trial remedy dispute could impact the interplay between monetary and injunctive relief in ongoing and future trade secret actions. Benesch attorneys will be watching the outcome of this dispute closely. If you have any questions, please reach out to:
Katie Burnett at kburnett@beneschlaw.com or 312.624.6357.
Samantha Marchand at smarchand@beneschlaw.com or 312.212.4938.
Latest News
SDNY Bankruptcy Court: Solvent Debtors Face Higher Hurdle to Avoid Default Interest Under 11 U.S.C. § 506(b)
Key Takeaways Following a recent decision from the U.S. Bankruptcy Court for the Southern District of New York, solvent debtors …
$2B Trade Secrets Verdict Overturned by the Virginia Supreme Court
Recently, the Virginia Supreme Court vacated a $2B jury award and ordered a new trial in a state trade secrets action. The justices held that the circuit court judge made four significant errors leading to Virginia’s largest jury award. Significantly, according to the justices, the circuit court judge put an improper burden of proof on defendants to show that its sales were unrelated to the misappropriation to avoid plaintiff being awarded defendant’s full sales revenue as opposed to the plaintiff having the burden to show defendant’s actions proximately caused plaintiff’s damages.
Ohio Senate Introduces Bipartisan Bill to Establish Paid Family and Medical Leave
On April 23, 2026, a new bipartisan bill was introduced in the Ohio Senate that would provide paid family and medical leave to Ohio workers. Sponsored by Democrat Beth Litson and Republican Louis W. Blessing III, Senate Bill 396 largely mirrors programs already established in several other states, including California and New York.
Medical First, Recreational Later? DOJ’s Cannabis Order and the Stakes Ahead
DOJ’s April 2026 order immediately moved FDA-approved and state-licensed medical cannabis to Schedule III, removing harsh tax penalties for medical operators, while leaving adult-use cannabis under stricter Schedule I controls pending further administrative review.